Perceptive Advisors
Latest statistics and disclosures from Perceptive Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CERE, FOLD, LIAN, ACLX, NUVL, and represent 35.61% of Perceptive Advisors's stock portfolio.
- Added to shares of these 10 stocks: RYTM (+$82M), Cargo Therapeutics (+$80M), SYRE (+$54M), AXSM (+$44M), BHVN (+$42M), NTRA (+$40M), CERE (+$37M), ABBV (+$37M), NUVL (+$33M), ACLX (+$32M).
- Started 21 new stock positions in Revolution Medicines, BCAB, ABBV, AUTL, OLMA, MGNX, XBI, MLTX, CYTK, ARVN. CELC, ISRG, ACAD, MORF, Ambrx Biopharma, Cargo Therapeutics, ASND, ITCI, EWTX, RGNX, APLT.
- Reduced shares in these 10 stocks: ARGX (-$74M), IMVT (-$63M), ROIV (-$45M), AKRO (-$34M), HRMY (-$33M), RLAY (-$16M), PCVX (-$16M), PTGX (-$15M), RVMD (-$14M), TNGX (-$13M).
- Sold out of its positions in SLRN, ACRS, APLS, ARQT, ARGX, BMEA, Eqrx, ETNB, HRMY, Motus Gi Hldgs. OM, Point Biopharma Global, RLAY, Somalogic, VKTX, PRTA, ROIV.
- Perceptive Advisors was a net buyer of stock by $433M.
- Perceptive Advisors has $4.5B in assets under management (AUM), dropping by 46.51%.
- Central Index Key (CIK): 0001224962
Tip: Access up to 7 years of quarterly data
Positions held by Perceptive Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Perceptive Advisors
Perceptive Advisors holds 99 positions in its portfolio as reported in the December 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Cerevel Therapeutics Hldng I (CERE) | 10.4 | $465M | +8% | 11M | 42.40 |
|
Amicus Therapeutics (FOLD) | 8.9 | $398M | 28M | 14.19 |
|
|
Lianbio Sponsored Ads (LIAN) | 5.8 | $257M | 58M | 4.47 |
|
|
Arcellx Common Stock (ACLX) | 5.7 | $252M | +14% | 4.5M | 55.50 |
|
Nuvalent Inc-a (NUVL) | 4.8 | $215M | +18% | 2.9M | 73.59 |
|
Inhibrx (INBX) | 3.6 | $162M | 4.3M | 38.00 |
|
|
Soleno Therapeutics (SLNO) | 2.8 | $124M | 3.1M | 40.25 |
|
|
Rhythm Pharmaceuticals (RYTM) | 2.2 | $99M | +465% | 2.2M | 45.97 |
|
Immunovant (IMVT) | 2.2 | $98M | -38% | 2.3M | 42.13 |
|
Iovance Biotherapeutics (IOVA) | 2.2 | $97M | 12M | 8.13 |
|
|
Cymabay Therapeutics (CBAY) | 2.1 | $95M | 4.0M | 23.62 |
|
|
Axsome Therapeutics (AXSM) | 1.9 | $83M | +115% | 1.0M | 79.59 |
|
Medtronic SHS (MDT) | 1.8 | $81M | +66% | 977k | 82.38 |
|
Cargo Therapeutics | 1.8 | $80M | NEW | 3.4M | 23.15 |
|
Meiragtx Holdings (MGTX) | 1.8 | $80M | 11M | 7.02 |
|
|
Verona Pharma Sponsored Ads (VRNA) | 1.7 | $77M | -3% | 3.9M | 19.88 |
|
Biohaven (BHVN) | 1.7 | $74M | +129% | 1.7M | 42.80 |
|
Springworks Therapeutics (SWTX) | 1.6 | $71M | +28% | 2.0M | 36.50 |
|
Bridgebio Pharma (BBIO) | 1.6 | $71M | 1.7M | 40.37 |
|
|
Vaxcyte (PCVX) | 1.5 | $68M | -18% | 1.1M | 62.80 |
|
Lyra Therapeutics (LYRA) | 1.5 | $67M | 13M | 5.24 |
|
|
Disc Medicine (IRON) | 1.3 | $59M | +14% | 1.0M | 57.76 |
|
Spyre Therapeutics Com New (SYRE) | 1.3 | $56M | +3113% | 2.6M | 21.52 |
|
Natera (NTRA) | 1.2 | $53M | +289% | 850k | 62.64 |
|
Rapt Therapeutics (RAPT) | 1.2 | $53M | +11% | 2.1M | 24.85 |
|
Verrica Pharmaceuticals (VRCA) | 1.2 | $52M | +40% | 7.1M | 7.32 |
|
Rocket Pharmaceuticals (RCKT) | 1.1 | $51M | +12% | 1.7M | 29.97 |
|
Apogee Therapeutics (APGE) | 1.1 | $51M | 1.8M | 27.94 |
|
|
Xenon Pharmaceuticals (XENE) | 1.1 | $51M | +78% | 1.1M | 46.06 |
|
Rayzebio (RYZB) | 1.0 | $46M | -4% | 744k | 62.17 |
|
Cabaletta Bio (CABA) | 1.0 | $46M | +76% | 2.0M | 22.70 |
|
Crinetics Pharmaceuticals In (CRNX) | 1.0 | $45M | 1.3M | 35.58 |
|
|
Sarepta Therapeutics (SRPT) | 1.0 | $44M | +59% | 452k | 96.43 |
|
Evolus (EOLS) | 0.9 | $42M | +166% | 4.0M | 10.53 |
|
Miragen Therapeutics (VRDN) | 0.8 | $38M | +71% | 1.7M | 21.78 |
|
Nautilus Biotechnology (NAUT) | 0.8 | $38M | +38% | 13M | 2.99 |
|
Abbvie (ABBV) | 0.8 | $37M | NEW | 238k | 154.97 |
|
Immatics SHS (IMTX) | 0.8 | $37M | 3.5M | 10.53 |
|
|
Neurocrine Biosciences (NBIX) | 0.8 | $36M | +70% | 271k | 131.76 |
|
Madrigal Pharmaceuticals (MDGL) | 0.8 | $35M | +21% | 151k | 231.38 |
|
Astria Therapeutics (ATXS) | 0.7 | $31M | +82% | 4.0M | 7.68 |
|
Aldeyra Therapeutics (ALDX) | 0.7 | $30M | -24% | 8.6M | 3.51 |
|
Adma Biologics (ADMA) | 0.7 | $29M | -7% | 6.4M | 4.52 |
|
Amylyx Pharmaceuticals (AMLX) | 0.6 | $28M | -30% | 1.9M | 14.72 |
|
Fusion Pharmaceuticals (FUSN) | 0.6 | $26M | 2.8M | 9.61 |
|
|
Tarsus Pharmaceuticals (TARS) | 0.6 | $26M | 1.3M | 20.25 |
|
|
Revolution Medicines (RVMD) | 0.5 | $24M | -38% | 819k | 28.68 |
|
Akero Therapeutics (AKRO) | 0.5 | $23M | -59% | 968k | 23.35 |
|
Health Sciences Acq Corp 2 (OBIO) | 0.5 | $22M | 2.4M | 9.13 |
|
|
Celcuity (CELC) | 0.5 | $22M | NEW | 1.5M | 14.57 |
|
Solid Biosciences Com New (SLDB) | 0.5 | $22M | 3.5M | 6.14 |
|
|
Intuitive Surgical Com New (ISRG) | 0.4 | $19M | NEW | 55k | 337.36 |
|
CryoLife (AORT) | 0.4 | $17M | 931k | 17.88 |
|
|
Ascendis Pharmaa/s Sponsored Adr (ASND) | 0.4 | $17M | NEW | 132k | 125.95 |
|
Treace Med Concepts (TMCI) | 0.4 | $16M | -31% | 1.3M | 12.75 |
|
Mirum Pharmaceuticals (MIRM) | 0.4 | $16M | -20% | 535k | 29.52 |
|
Acrivon Therapeutics Common Stock (ACRV) | 0.3 | $15M | 3.0M | 4.92 |
|
|
Arvinas Ord (ARVN) | 0.3 | $15M | NEW | 354k | 41.16 |
|
Athira Pharma (ATHA) | 0.3 | $13M | +12% | 5.4M | 2.43 |
|
Autolus Therapeutics Spon Ads (AUTL) | 0.3 | $12M | NEW | 1.8M | 6.44 |
|
Zymeworks Del (ZYME) | 0.3 | $11M | -25% | 1.1M | 10.39 |
|
Tango Therapeutics (TNGX) | 0.2 | $11M | -54% | 1.1M | 9.90 |
|
Tactile Systems Technology, In (TCMD) | 0.2 | $10M | 707k | 14.30 |
|
|
Protagonist Therapeutics (PTGX) | 0.2 | $8.8M | -63% | 383k | 22.93 |
|
Intra Cellular Therapies (ITCI) | 0.2 | $7.7M | NEW | 108k | 71.62 |
|
Olema Pharmaceuticals (OLMA) | 0.2 | $7.6M | NEW | 540k | 14.03 |
|
Terns Pharmaceuticals (TERN) | 0.2 | $7.0M | 1.1M | 6.49 |
|
|
Cogent Biosciences (COGT) | 0.1 | $6.6M | -51% | 1.1M | 5.88 |
|
Regenxbio Inc equity us cm (RGNX) | 0.1 | $6.1M | NEW | 342k | 17.95 |
|
Edgewise Therapeutics (EWTX) | 0.1 | $6.1M | NEW | 556k | 10.94 |
|
Macrogenics (MGNX) | 0.1 | $5.9M | NEW | 612k | 9.62 |
|
Axogen (AXGN) | 0.1 | $5.5M | -7% | 808k | 6.83 |
|
Landos Biopharma Com New (LABP) | 0.1 | $5.4M | 1.5M | 3.66 |
|
|
Tyra Biosciences (TYRA) | 0.1 | $5.0M | 360k | 13.85 |
|
|
Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.1 | $5.0M | NEW | 82k | 60.39 |
|
Novavax Com New Put Option (NVAX) | 0.1 | $4.8M | +7% | 1.4M | 3.40 |
|
Applied Therapeutics Call Option (APLT) | 0.1 | $4.6M | NEW | 4.6M | 1.00 |
|
Nanobiotix Sponsored Ads (NBTX) | 0.1 | $4.0M | 555k | 7.28 |
|
|
Female Health (VERU) | 0.1 | $4.0M | +412% | 5.6M | 0.72 |
|
Travere Therapeutics (TVTX) | 0.1 | $3.6M | 400k | 8.99 |
|
|
Envveno Medical (NVNO) | 0.1 | $3.2M | -20% | 623k | 5.14 |
|
ACADIA Pharmaceuticals (ACAD) | 0.1 | $3.2M | NEW | 101k | 31.31 |
|
X4 Pharmaceuticals (XFOR) | 0.1 | $3.0M | 3.5M | 0.84 |
|
|
Forte Biosciences (FBRX) | 0.1 | $2.7M | 3.3M | 0.82 |
|
|
Cytokinetics Com New (CYTK) | 0.1 | $2.5M | NEW | 30k | 83.49 |
|
Kronos Bio (KRON) | 0.0 | $2.2M | 1.8M | 1.25 |
|
|
Establishment Labs Holdings Ord (ESTA) | 0.0 | $2.1M | -70% | 82k | 25.89 |
|
Caremax Com Cl A (CMAX) | 0.0 | $1.8M | -3% | 3.7M | 0.50 |
|
Morphic Hldg (MORF) | 0.0 | $1.6M | NEW | 57k | 28.88 |
|
Spdr Ser Tr S&p Biotech Put Option (XBI) | 0.0 | $1.3M | NEW | 1.9M | 0.67 |
|
Ambrx Biopharma | 0.0 | $1.1M | NEW | 79k | 14.24 |
|
Singular Genomics Systems In (OMIC) | 0.0 | $979k | -9% | 2.1M | 0.46 |
|
Vbi Vaccines Inc Cda Com New (VBIV) | 0.0 | $815k | 1.4M | 0.59 |
|
|
Leap Therapeutics Com New (LPTX) | 0.0 | $186k | 45k | 4.14 |
|
|
Bioatla (BCAB) | 0.0 | $180k | NEW | 73k | 2.46 |
|
Revolution Medicines *w Exp 12/17/202 | 0.0 | $83k | NEW | 250k | 0.33 |
|
Eyepoint Pharmaceuticals Com New Put Option (EYPT) | 0.0 | $67k | +78% | 1.3M | 0.05 |
|
Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $3.3k | 167k | 0.02 |
|
|
Caremax *w Exp 06/08/202 (CMAXW) | 0.0 | $450.000000 | 60k | 0.01 |
|
Past Filings by Perceptive Advisors
SEC 13F filings are viewable for Perceptive Advisors going back to 2010
- Perceptive Advisors 2023 Q4 restated filed Feb. 26, 2024
- Perceptive Advisors 2023 Q4 filed Feb. 14, 2024
- Perceptive Advisors 2023 Q3 filed Nov. 14, 2023
- Perceptive Advisors 2023 Q2 restated filed Aug. 24, 2023
- Perceptive Advisors 2023 Q2 filed Aug. 14, 2023
- Perceptive Advisors 2023 Q1 restated filed May 16, 2023
- Perceptive Advisors 2023 Q1 filed May 15, 2023
- Perceptive Advisors 2022 Q4 filed Feb. 14, 2023
- Perceptive Advisors 2022 Q3 filed Nov. 14, 2022
- Perceptive Advisors 2022 Q2 filed Aug. 15, 2022
- Perceptive Advisors 2022 Q1 filed May 16, 2022
- Perceptive Advisors 2021 Q4 amended filed May 4, 2022
- Perceptive Advisors 2021 Q4 restated filed April 13, 2022
- Perceptive Advisors 2021 Q4 filed Feb. 14, 2022
- Perceptive Advisors 2021 Q3 restated filed Dec. 3, 2021
- Perceptive Advisors 2021 Q3 filed Nov. 15, 2021